| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7736665 | TITAN PHARMS | Implantable polymeric device for sustained release of buprenorphine |
Apr, 2024
(6 months from now) | |
Probuphine is owned by Titan Pharms.
Probuphine contains Buprenorphine Hydrochloride.
Probuphine has a total of 1 drug patent out of which 0 drug patents have expired.
Probuphine was authorised for market use on 26 May, 2016.
Probuphine is available in implant;implantation dosage forms.
Probuphine can be used as for opioid dependence.
The generics of Probuphine are possible to be released after 25 April, 2024.
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2016
Treatment: For opioid dependence
Dosage: IMPLANT;IMPLANTATION
PROBUPHINE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic